Overview of HIV Drugs MarketThe Global HIV Drugs Market is valued at USD 34.75 Billion in 2024 and is projected to reach a ...

Regarding cuts and uncertainty regarding funding reductions to the President's Emergency Plan for AIDS Relief (PEPFAR), Kaseya said six African countries are on the verge of running out of ...

Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...

Neonates require potent antiretroviral drugs (ARVs) against HIV but there are fewer drugs available for children compared to adults. Administering the correct neonatal dose of ARVs can be ...

Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

shows that IMC-M113V – the first T cell receptor bispecific therapy to target HIV in the clinic – is well tolerated and shows signals of dose-dependent viral control after antiretroviral ...

Sabrina Carpenter's impact on the Official Albums Chart is anything but Short N’ Sweet as she claims the Number 1 album of 2025 so far. Racking up 196,000 chart units this year alone (with an ...

In the fight against HIV, one of the most vulnerable populations is often overlooked - newborn babies It is estimated that 120,000 new HIV infections occur in children aged 14 years and younger ...

For the once-yearly study, researchers at Gilead examined two intramuscular presentations of lenacapavir given in a 5-g dose, formulated ... from HIV sales boost, charts course for long-acting ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...